Trial reportFrontiers in veterinary science2026
Efficacy and safety of supplementation of Exclzyme Pet for the management of arthritis and inflammatory symptoms in dogs: a randomized, double-blind, placebo-controlled pilot trial.
Trial report in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A randomized, double-blind, placebo-controlled interventional pilot trial was conducted to evaluate the safety and efficacy of Exclzyme Pet in alleviating clinical symptoms associated with canine arthritis. Methods: A total of 26 client-owned dogs exhibiting clinical signs of arthritis were enrolled in a 30-day pilot trial, of which 23 completed the study. Subjects were randomly allocated to either the treatment group ( Results: Exclzyme Pet resulted in a statistically significant reduction in scores for lameness, weight bearing, joint mobility, willingness to hold up contralateral limb, and pain by 51.96, 46.94, 48.94, 58.0, and 55.56%, respectively and demonstrated clear superiority over placebo. The overall quality of life, mood, and mobility improved significantly in the treatment group over the placebo. Serum C-reactive protein levels decreased markedly by 56.10% in dogs receiving Exclzyme Pet, whereas levels increased by 15.38% in the placebo group, indicating a strong anti-inflammatory effect ( Conclusion: In conclusion, Exclzyme Pet demonstrated significant efficacy in reducing clinical signs of arthritis and improving functional outcomes in dogs, with no evident safety concerns during the entire study period. These results suggest that Exclzyme Pet may serve as a safe and effective adjunctive therapy for managing canine arthritis. Nevertheless, longer-duration clinical trials with large study population are needed to confirm these findings and further elucidate the mechanisms its therapeutic effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.